Since amyloidogenic APP processing is initiated by lipid raft-dependent processes, raft disruption and reduced proximity of components of the amyloidogenic pathway induced by decreased cholesterol levels result in lower Aβ levels and neurotoxicity both in vitro and in vivo, which provides the basis of their potential therapeutic application in Alzheimer’s disease, as recently reviewed [205,206,207]. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.